Amylyx CEO Justin Klee Receives 60,039-Share Award

What Happened
Justin B. Klee, CEO of Amylyx Pharmaceuticals (AMLX), was issued 60,039 shares on August 18, 2026 as the result of performance share units (PSUs) vesting. The filing reports an acquisition (code A) of 60,039 shares at $0.00 (total reported value $0), reflecting award/vesting rather than a cash purchase.

Key Details

• Transaction date: August 18, 2026; Form 4 filed August 20, 2026 (within the usual 2‑business‑day reporting window).
• Transaction type/code: Award/Grant (A) — shares issued upon PSU vesting.
• Shares acquired: 60,039; reported price per share: $0.00; reported aggregate value: $0.
• Shares owned after transaction: not specified in the information provided.
• Footnote: The shares were represented by PSUs awarded upon achievement of specified performance metrics; the PSUs vested on August 18, 2026 (Footnote F1).
• No indication of a 10b5-1 sale plan, cashless exercise, tax withholding, or immediate disposition in the provided filing.

Context
PSUs convert to actual shares when performance conditions are met; this entry reflects compensation-based vesting rather than an open-market buy or sale. Such awards increase insider share ownership but are not a direct cash investment decision.